Integra LifeSciences Holdings Corporation Stock

Equities

IART

US4579852082

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-07-02 pm EDT 5-day change 1st Jan Change
29.19 USD +0.76% Intraday chart for Integra LifeSciences Holdings Corporation +1.28% -32.97%
Sales 2024 * 1.68B Sales 2025 * 1.77B Capitalization 2.3B
Net income 2024 * 95M Net income 2025 * 157M EV / Sales 2024 * 2.14 x
Net Debt 2024 * 1.29B Net Debt 2025 * 1.44B EV / Sales 2025 * 2.11 x
P/E ratio 2024 *
25.6 x
P/E ratio 2025 *
15.8 x
Employees 3,946
Yield 2024 *
-
Yield 2025 *
-
Free-Float 74.08%
More Fundamentals * Assessed data
Dynamic Chart
Integra LifeSciences Holdings Corporation(NasdaqGS:IART) added to S&P 600 Health Care CI
Integra LifeSciences Holdings Corporation(NasdaqGS:IART) added to S&P 600 CI
Integra LifeSciences Holdings Corporation(NasdaqGS:IART) dropped from S&P 400 Health Care CI
Integra LifeSciences Holdings Corporation(NasdaqGS:IART) dropped from S&P 400 CI
KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24 MT
Integra Lifesciences Holdings Insider Bought Shares Worth $1,499,979, According to a Recent SEC Filing MT
Integra Lifesciences Holdings Insider Bought Shares Worth $995,816, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday MT
Integra LifeSciences Holdings to Repurchase $50 Million in Shares MT
Transcript : Integra LifeSciences Holdings Corporation Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM
Truist Cuts Price Target on Integra LifeSciences Holdings to $25 From $37, Keeps Hold Rating MT
Wells Fargo Downgrades Integra LifeSciences Holdings to Equalweight From Overweight, Cuts Price Target to $25 From $45 MT
Oppenheimer Downgrades Integra LifeSciences Holdings to Perform From Outperform MT
Tranche Update on Integra LifeSciences Holdings Corporation's Equity Buyback Plan announced on July 27, 2023. CI
Integra LifeSciences Shares Drop to Record Low on Unexpected Loss, Boston Facility Audit Findings DJ
More news
1 day+0.76%
1 week+1.28%
Current month+0.17%
1 month-5.53%
3 months-12.92%
6 months-32.51%
Current year-32.97%
More quotes
1 week
28.29
Extreme 28.29
30.40
1 month
28.11
Extreme 28.11
32.28
Current year
22.36
Extreme 22.36
45.42
1 year
22.36
Extreme 22.36
46.75
3 years
22.36
Extreme 22.36
76.70
5 years
22.36
Extreme 22.36
77.40
10 years
22.36
Extreme 22.36
77.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 21-11-30
Director of Finance/CFO 52 23-06-27
Chairman 62 97-11-30
Members of the board TitleAgeSince
Director/Board Member 62 Dec. 11
Chairman 62 97-11-30
Director/Board Member 63 05-12-31
More insiders
Date Price Change Volume
24-07-02 29.19 +0.76% 735,545
24-07-01 28.97 -0.58% 1,014,830
24-06-28 29.14 +1.36% 10,427,038
24-06-27 28.75 +0.63% 803,646
24-06-26 28.57 -0.87% 1,425,411

Delayed Quote Nasdaq, July 02, 2024 at 04:00 pm EDT

More quotes
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
29.19 USD
Average target price
34.2 USD
Spread / Average Target
+17.16%
Consensus